Progenics Pharmaceuticals, Inc. (PGNX) Reports In-Line Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Price: $4.10 --0%
Financial Fact:
Total other income: 79K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Total other income: 79K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) reported Q1 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $1.8 million versus the consensus estimate of $2.88 million.
For earnings history and earnings-related data on Progenics Pharmaceuticals, Inc. (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AI-powered cyber threats light a fire under cybersecurity stocks
- RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
